Roadrunner many here know your long term doubts and I think it is fair to repeat them so as to offer any newcomers ‘the other side of the story’ perspectives.
But in June - to address past commercial issues in the US - NXS created the new role of Chief Commercial Officer and appointed Dustin Haines into it.
His previous position was as President and General Manager of ViiV Healthcare, Tokyo which saw
Linkedin bio [Linkedin],
.... “ 7% growth YoY, top line sales 108% above plan, as well as producing highest franchise market share globally. Responsible for managing the business partnership with Shionogi Pharmaceuticals and delivering the strategic direction for the company...”
He is now part of the management team you say you believe is not capable but his resume belies that.
Also the deal locked in with 3M (which seems to have shafted NXS) will not remain locked forever,
... and the products seem to speak for themselves, and the Co-Vid 19 vaccines will open the door for resumption of a higher number of elective surgeries using Xbio in both the US and Europe, and this should be good for the company too?
cheers
Roadrunner many here know your long term doubts and I think it...
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $109.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.5¢ | $37.03K | 97.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 33285 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.5¢ |
Change
-0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 38.5¢ | 39.0¢ | 37.5¢ | 6130 | ||
| Last updated 14.36pm 15/05/2024 ? | |||||
| NXS (ASX) Chart |